SCOTTSDALE, Ariz. – October 30, 2026 -- LifeStance Health (Nasdaq: LFST) reports that 74% of its patients with treatment-resistant depression achieved a clinically meaningful reduction in symptoms after 12 weeks of esketamine (Spravato), while 61% of TMS patients improved after at least 30 sessions. The outpatient mental healthcare provider is expanding access to both specialty services across the U.S.